Related Experiment Video
Updated: May 8, 2026
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Indirubin derivative 6BIO suppresses metastasis
Simone Braig1, Christine A Kressirer, Johanna Liebl
1Authors' Affiliations: Pharmaceutical Biology, Department of Pharmacy, University of Munich, Munich, Germany; and Centre Nationale de la Recherche Scientifique, Station Biologique, Roscoff, France.
Cancer Research
|August 16, 2013
Summary
The novel compound 6-bromo-indirubin-3'-oxime (6BIO) effectively inhibits cancer metastasis by targeting multiple kinase pathways. This polypharmacology approach offers a promising strategy against aggressive breast cancer spread.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Metastasis is the primary cause of cancer-related deaths, yet effective antimetastatic therapies are limited.
- Developing novel agents to combat cancer cell spread is a critical unmet need in clinical oncology.
Purpose of the Study:
- To evaluate the antimetastatic potential of the indirubin derivative 6-bromo-indirubin-3 -oxime (6BIO).
- To investigate the molecular mechanisms underlying 6BIO's antimetastatic activity in aggressive breast cancer.
Main Methods:
- Utilized the 4T1 mouse model for aggressive breast cancer lung metastasis.
- Assessed 6BIO's effects on cancer cell adhesion, migration, and invasion in vitro.
- Employed RNA interference (RNAi) to silence key signaling pathways, including GSK3β, PDK1, and Jak/STAT3.
Main Results:
- 6BIO significantly reduced lung metastasis formation in vivo.
- Subtoxic concentrations of 6BIO inhibited cancer cell adhesion, migration, and invasion.
- While Jak/STAT3 was identified as a major pathway, GSK3β and PDK1 also contributed to 6BIO's antimetastatic effects.
Conclusions:
- 6BIO demonstrates potent antimetastatic activity by simultaneously inhibiting multiple kinase signaling cascades.
- This study supports the concept of polypharmacology for developing effective anti-metastatic drugs.
- 6BIO represents a promising therapeutic candidate for targeting the deadliest aspect of cancer.
